Drugs / ex vivo Activated Immune Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02169531 | Mar 2014 → Jun 2015 | hyperglycemia, type 2 diabetes mellitus | B & Y Technologies | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ex vivo Activated Immune Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02169531 ↗ |
| Modality | Cell therapy | “The cultured cells (autologous) will be infused intravenously back to patients.” NCT02169531 ↗ |
| Route | Intravenous | “will be infused intravenously back to patients” NCT02169531 ↗ |